Home / Cancer treatment in China / Colorectal cancer treatment

Advanced disease

Metastatic Colorectal Cancer Treatment

Metastatic colorectal cancer can be treated. Treated is not the same word as cured, and it is not the same word as resectable. Some liver or lung metastases can be removed. Others are treated with chemotherapy, sometimes with a targeted drug, to control disease or to try to make a later operation possible. RAS, NRAS, BRAF, MSI or MMR, and HER2 change which drugs are plausible. Radiation or ablation can matter for a defined lesion. A trial is a separate route, not an approved treatment.

Applicability: liver metastases, lung metastases, and peritoneal disease are not one situation. A scan report is not a surgical booking.

Review my case
Resectable is a surgical judgmentMarkers before drug namesA trial is not a label

Can colorectal liver metastases be treated surgically?

Some can. A liver surgeon looks at how many lesions there are, where they sit, how much healthy liver would remain, and whether the bowel tumor and any other metastases can also be controlled. Lung metastases can raise the same kind of question in the chest. Peritoneal disease is a different operation, when it is an operation at all.

What makes metastatic colorectal cancer resectable?

Resectable means a surgeon expects to remove the known disease with a margin the team accepts, and the person can tolerate that operation. It is not a synonym for Stage IV, and it is not a synonym for a good response on a scan. Prior treatment and the marker report still matter because the systemic plan continues around the operation.

Can treatment make an unresectable tumor resectable?

Sometimes. Conversion therapy means chemotherapy, often with a targeted drug chosen from the marker report, given with the aim of making a later operation possible. Many people do not become resectable. A shrinking scan is not itself an operation.

How do RAS, BRAF, MSI, and HER2 affect treatment?

RAS and NRAS mutations usually take anti-EGFR antibodies off the table. BRAF V600E is a worse-prognosis group with its own targeted combinations, described on the 2026 evidence page. MSI-H or dMMR is the group in which checkpoint immunotherapy can be a major option. HER2-positive disease has a later-line antibody-drug conjugate label in China for a defined population. MSS or pMMR disease is not treated as if it were MSI-H.

When is radiation relevant?

Radiation is a standard part of many rectal-cancer plans, including when metastases are also present and the pelvic tumor needs control. It is also used for selected painful or dangerous metastases. It is not a routine substitute for colon surgery, and it is not a reason to skip systemic therapy in widespread disease.

When may SBRT or another local therapy be considered?

Stereotactic body radiation, ablation, or another local treatment can be discussed for a limited metastasis when surgery is not the right tool or when a lesion needs local control. Those pages already exist for proton therapy, microwave ablation, and cryoablation. They are not universal alternatives to surgery or to chemotherapy.

When are clinical trials relevant?

A trial is relevant when the labelled options are exhausted, when a marker matches a study, or when a drug is not available outside a protocol. A registry record is not eligibility. Screening is not enrollment. The China access page is colorectal cancer treatment in China.

In this cluster

Technology pages already on this site, used only when a case actually needs them: proton therapy, microwave ablation, cryoablation, and interventional oncology. None of those replaces surgery or systemic therapy for colorectal cancer as a default.

Questions people ask

Can metastatic colorectal cancer be treated?

Yes. Treatment may be surgery for resectable metastases, systemic therapy, a local treatment for a defined lesion, or a trial. Those are different routes. Metastatic disease is not one regimen, and treatment is not a promise of cure.

Can colorectal cancer liver metastases be removed?

Some can, when a liver surgeon judges that the lesions can be removed and enough liver will remain, and the rest of the disease can be controlled. Others cannot. Chemotherapy is sometimes used first to try to make surgery possible. It does not make every case resectable.

What does BRAF V600E mean in colorectal cancer?

BRAF V600E is a mutation that marks a higher-risk metastatic colorectal cancer and opens specific targeted combinations. It is not the same finding as a RAS mutation. The China label verified on the 2026 page is encorafenib plus cetuximab after prior systemic therapy. A first-line combination in a guideline is a separate document.

Sources

  • NCI, Colon Cancer Treatment (PDQ) patient version. Used for the general distinction between colon treatment and a personal plan.
  • NCI, Rectal Cancer Treatment (PDQ) patient version. Used for the point that rectal cancer more often involves radiation than colon cancer.
  • National Health Commission colorectal cancer specification, 2025 edition. English summary: Chin J Cancer Res 2025;37(6):949-961. doi 10.21147/j.issn.1000-9604.2025.06.07. This is a practice framework, not a 2026 drug list.
  • CSCO colorectal guideline version 2026, as interpreted in Chin J Cancer Res 2026;38(3):329-335. doi 10.21147/j.issn.1000-9604.2026.03.10. The full guideline PDF was not pasted here.
  • Cao and Jiang, 1 October 2026. Digestive Oncology, electronic edition, 2026;18(3):358-363. Used for the metastatic nivolumab sentence, the stage III dMMR adjuvant sentence, and the first-line BRAF move.
  • CancerNetwork, 13 July 2025, reporting NMPA authorization of encorafenib plus cetuximab for adults with previously treated BRAF V600E metastatic colorectal cancer, from a Pierre Fabre release. BREAKWATER: Elez and colleagues, N Engl J Med 2025;392:2425-37. doi 10.1056/NEJMoa2501912.
  • Guangming, 10 August 2026, reporting NMPA wording for adults with HER2-positive colorectal cancer after failure of oxaliplatin, fluorouracil, and irinotecan. HORIZON-CRC01 was reported at ASCO 2026. This is company and news reporting, not an opened NMPA gazette page.

Last reviewed: 3 October 2026. A trial permission, a guideline sentence, and a drug label are three different documents.

Check a metastatic treatment question

Resectability and markers change the question. ParkMega does not decide operability or enroll a trial.

Message us on WhatsApp without this form